Cleerly ISCHEMIA vs VX1

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Cleerly ISCHEMIA

by Cleerly

VX1

by Volta Medical

AI Verdict

These tools are adjacent in their application within cardiology, rather than direct competitors. Cleerly ISCHEMIA focuses on non-invasive diagnosis and treatment planning for coronary artery ischemia using CCTA scans. In contrast, Volta Medical's VX1 provides real-time AI guidance during atrial fibrillation and atrial tachycardia ablation procedures, analyzing electrogram data.

Choose Cleerly ISCHEMIA if…

Choose Cleerly ISCHEMIA if you need a non-invasive, AI-powered diagnostic tool to assess the likelihood of coronary artery ischemia and characterize coronary plaque from CCTA scans. This is ideal for physicians seeking detailed, vessel-level insights to personalize diagnosis and treatment planning for patients with suspected or known coronary artery disease, prior to any interventional procedures.

View Cleerly ISCHEMIA →

Choose VX1 if…

Choose VX1 if you are a cardiac electrophysiologist performing atrial fibrillation or atrial tachycardia ablation procedures and require real-time AI guidance. This tool is specifically designed to assist in identifying dispersed electrograms during the procedure, aiming to reduce inter-operator variability and standardize outcomes in the EP lab.

View VX1 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Cleerly ISCHEMIA	VX1
Pricing	Unknown	Contact for pricing
Deployment	Web-based solution	Software integrated with existing electrophysiology (EP) lab mapping and recording systems.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cleerly ISCHEMIA

Cleerly ISCHEMIA operates on a web-based platform and provides comprehensive interactive web-based reports, suggesting a user-friendly interface for reviewing results and facilitating broader access. While VX1 integrates with existing EP lab systems for real-time use, the specific usability of its dedicated interface for interaction and output review is not detailed in the provided information.

Clinical Value

Tie

Both tools offer significant, FDA-cleared clinical value in distinct areas of cardiology. Cleerly ISCHEMIA aids in non-invasive diagnosis and treatment planning for coronary artery disease, while Volta Medical VX1 enhances the efficacy and standardization of AFib and atrial tachycardia ablation procedures. Both address critical needs within their respective sub-specialties.

Pricing & Value

Tie

Neither tool provides transparent pricing information, with both requiring direct contact for details. Without specific pricing structures or detailed return on investment (ROI) data, it is impossible to conduct a meaningful head-to-head comparison of their value propositions.

Enterprise Readiness

Cleerly ISCHEMIA

Cleerly ISCHEMIA explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for enterprise adoption in healthcare. Its web-based deployment via Cleerly Proxy and integration with PowerScribe via API also indicate strong readiness for diverse IT environments. Volta Medical VX1, while FDA-cleared, does not explicitly state HIPAA compliance or BAA availability in the provided facts.

Innovation

Tie

Both tools demonstrate significant innovation by applying AI to complex, high-impact problems in cardiology. Cleerly ISCHEMIA innovates with non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA. Volta Medical VX1 offers real-time AI-guided identification of dispersed electrograms during ablation procedures, aiming to standardize outcomes and reduce variability.

Support & Docs

Tie

The provided structured facts and general web searches do not offer sufficient specific details regarding the availability, quality, or scope of support services and documentation for either Cleerly ISCHEMIA or Volta Medical VX1. Therefore, a meaningful comparison on this dimension cannot be made.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Cleerly ISCHEMIA	VX1
Name	Cleerly ISCHEMIA	VX1
Company	Cleerly	Volta Medical
Tagline	AI-Powered Precision for Non-Invasive Ischemia Detection	Transforming EP Data into AI Solutions
Primary Use Case	Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease.	Assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.
Specialties	Cardiology, Radiology	Cardiology
Core AI Analysis	AI-enabled CCTA analysis; Non-invasive fractional flow reserve (FFR) estimation; Vessel-level ischemia likelihood determination; Coronary plaque characterization (volume, type, location); Stenosis severity assessment; 3D digital models of coronary arteries.	AI-guided real-time identification of dispersed electrograms (EGMs); Analyzes 3D anatomical and electrical maps of human atria; Provides cycle length estimation from electrograms.

Videos

Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and VX1.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of Cleerly ISCHEMIA and Volta Medical VX1?

Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. Volta Medical's VX1 is an FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.

How do these tools integrate into a physician's existing workflow?

Cleerly ISCHEMIA is a web-based platform, with data transfer facilitated via Cleerly Proxy, which can be a VPN or virtual appliance, and offers integration with PowerScribe via API. Volta Medical's VX1 is software designed to integrate with existing electrophysiology (EP) lab mapping and recording systems, and is compatible with most EP recording, 3D navigation systems, and mapping catheters.

What specific types of data do these AI tools analyze?

Cleerly ISCHEMIA analyzes CCTA (Coronary Computed Tomography Angiography) scans to characterize coronary plaque, assess stenosis severity, and estimate non-invasive fractional flow reserve (FFR). Volta Medical's VX1 analyzes 3D anatomical and electrical maps of human atria and electrograms in real-time to identify dispersed electrograms.

What are the key outputs or insights provided by each tool?

Cleerly ISCHEMIA provides vessel-level ischemia likelihood determination, non-invasive fractional flow reserve (FFR) estimation, coronary plaque characterization (volume, type, location), stenosis severity assessment, and comprehensive interactive web-based reports with 3D digital models of coronary arteries. Volta Medical's VX1 provides AI-guided real-time identification of dispersed electrograms, cycle length estimation from electrograms, and offers a booster mode for increased sensitivity during AT or slow AF.

Which medical specialties are these tools primarily designed for?

Cleerly ISCHEMIA is designed for Cardiology and Radiology, focusing on the diagnostic assessment of heart disease through CCTA analysis. Volta Medical's VX1 is primarily for Cardiology, specifically assisting cardiac electrophysiologists during atrial fibrillation and atrial tachycardia ablation procedures.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Cleerly ISCHEMIA or VX1

Backers

Who funded each tool's parent company.